Literature DB >> 17038908

A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.

S Joseph Kim1, G V Ramesh Prasad, Michael Huang, Michelle M Nash, Olusegun Famure, Joseph Park, Mary Ann Thenganatt, Nizamuddin Chowdhury, Edward H Cole, Stanley S A Fenton, Daniel C Cattran, Jeffrey S Zaltzman, Carl J Cardella.   

Abstract

BACKGROUND: There are few data directly comparing the effects of two-hour postingestion monitored cyclosporine (C2-CsA) vs. trough-monitored tacrolimus (C0-Tac) on renal function and cardiovascular risk factors.
METHODS: We studied 378 (202 C2-CsA vs. 176 C0-Tac) incident kidney transplant recipients in Toronto, Canada, from August 1, 2000 and December 31, 2003. Outcomes included changes in estimated glomerular filtration rate (eGFR at 1 and 6 months by modification of diet in renal disease four-variable equation), mean arterial pressure (MAP), total cholesterol (TC), and new-onset diabetes mellitus (NODM) at six months posttransplant. The independent effect of treatment/monitoring strategies on continuous outcomes and time-to-NODM was modeled using linear and Cox regression, respectively.
RESULTS: Mean eGFR was 59.5 vs. 62.9 ml/min at one month and 50.6 vs. 61.2 ml/min at six months for C2-CsA vs. C0-Tac, respectively. Multiple linear regression revealed the slope of eGFR to be 0.93 ml/min/month lower in C2-CsA patients. This was equivalent to an adjusted average eGFR difference of 4.64 ml/min between months one and six posttransplant. There was no significant difference in average MAP and TC. In a stepwise multivariable Cox model and a propensity score analysis, there was no significant association between the type of treatment/monitoring strategy and time-to-NODM.
CONCLUSIONS: There was a greater decline in eGFR for patients on C2-CsA (vs. C0-Tac) between one and six months posttransplant. However, MAP, TC, and the risk of NODM were comparable in both treatment/monitoring groups. The long-term impact of short-term reductions in eGFR as a function of the type of treatment/monitoring strategy requires further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038908     DOI: 10.1097/01.tp.0000239313.83735.33

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  New-onset diabetes mellitus after kidney transplantation: Current status and future directions.

Authors:  Sneha Palepu; G V Ramesh Prasad
Journal:  World J Diabetes       Date:  2015-04-15

2.  Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.

Authors:  Lynda A Frassetto; Clara C Tan-Tam; Burc Barin; Matt Browne; Alan R Wolfe; Peter G Stock; Michelle Roland; Leslie Z Benet
Journal:  Transplantation       Date:  2014-03-27       Impact factor: 4.939

3.  Post-transplant Diabetes Mellitus in Kidney Transplant Recipients in Sudan: A Comparison Between Tacrolimus and Cyclosporine-Based Immunosuppression.

Authors:  Elamein Yousif; Abdelrahman Abdelwahab
Journal:  Cureus       Date:  2022-02-16

4.  Tacrolimus Modulates TGF-β Signaling to Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells.

Authors:  Jason Bennett; Hilary Cassidy; Craig Slattery; Michael P Ryan; Tara McMorrow
Journal:  J Clin Med       Date:  2016-04-26       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.